Dear Doctor - Participate in the Survey on fecal microbiota transplantation "Fecal microbiota transplantation (FMT) is a procedure in which stool from a healthy donor is transplanted into the gastrointestinal tract of a person with a gut disorder. The goal of FMT is to restore the composition and function of the gut microbiome.Research on FMT is still in its early stages, but preliminary studies suggest that it may be an effective treatment for a variety of gut disorders, including Clostridium difficile infection (CDI), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). In addition, because the gut microbiome plays a role in immunity, there is interest in using FMT as a treatment for autoimmune diseases such as Crohn's disease and type 1 diabetes.Side effects of FMT are generally minor and include abdominal pain, bloating, diarrhea, and constipation. However, serious complications have been reported in rare cases, such as sepsis (a potentially life-threatening condition caused by infection).If you are considering FMT for yourself or a loved one, it is important to speak with a healthcare provider who is experienced in this procedure. Participate in Surveys "
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Review looks at potential treatment targets in the tumor microenvironment.
3.
Even when they are not paying attention, children are still learning.
4.
The Benefits of Exercise for Substance Use Disorders.
5.
The top three drugs for multiple myeloma treatment upfront are four.
1.
The New Era of Oncology: Key Updates and Clinical Insights
2.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
3.
Decoding Granular Cell Tumor: What You Need to Know
4.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
5.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Navigating the Complexities of Ph Negative ALL - Part XI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation